BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 20110046)

  • 1. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
    Mahtani RL; Stein A; Vogel CL
    Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
    Lavrenkov K; Man S; Geffen DB; Cohen Y
    Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y; Kawazoe T; Iwase H
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
    Ansari TN; Mahmood A; Hussain I; Samad A
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
    Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
    Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
    Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
    Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
    Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
    Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
    Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
    Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
    J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.